Structure Therapeutics (NASDAQ:GPCR) Shares Down 8.1% - Here's What Happened

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) traded down 8.1% on Tuesday . The stock traded as low as $43.98 and last traded at $43.5260. 751,091 shares were traded during trading, a decline of 14% from the average daily volume of 872,345 shares. The stock had previously closed at $47.34. A number of research analysts recently weighed in on GPCR shares. HC Wainwright decreased their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating on the stock in a research note on Thursday, June 11th. Citigroup reissued a "market outperform" rating on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research report on Friday, August 7th. Finally, Citizens Jmp reduced their price objective on Structure Therapeutics from $113.00 to $110.00 and set a "market outperform" rating for the company in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $110.91. Read Our Latest Report on Structure Therapeutics The firm's fifty day moving average is $50.68 and its 200-day moving average is $49.21. The stock has a market capitalization of $2.97 billion, a PE ratio of -42.88 and a beta of -1.45. Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.84 EPS for the current year. A number of hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC purchased a new stake in Structure Therapeutics in the 1st quarter valued at $28,000. State of Wyoming acquired a new position in Structure Therapeutics in the second quarter valued at $28,000. CWM LLC increased its stake in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company's stock valued at $33,000 after purchasing an additional 125 shares during the period. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company's stock valued at $123,000 after buying an additional 449 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $127,000. 91.78% of the stock is owned by hedge funds and other institutional investors. Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company's scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.The company's pipeline comprises multiple programs in various stages of preclinical and clinical development. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com. Before you consider Structure Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list. While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.